The world is changing all around us. Healthcare is
constantly changing and evolving, as new and better ways of providing patient
care are helping to save lives and improve the quality of life for those in
need. Critical Diagnostics is a company on the cutting edge of this change,
focused on the discovery, development, and commercialization of novel
biomarkers in cardiovascular diseases.
Our lead product, the Presage® ST2 Assay, has received FDA
clearance and is CE Marked in Europe. This simple, non-invasive test measures
for soluble ST2 in the blood, which can aid physicians in risk assessment of
chronic heart failure patients.
Soluble ST2 has now been published in more than 100
peer-reviewed articles and scientific posters studying more than 36,000
patients. These clinical studies have demonstrated that high levels of soluble
ST2 are predictive of adverse patient outcomes and death in chronic heart
failure. They have further shown that the prognostic information from soluble
ST2 is independent and provides added information to the cardiac biomarkers
commonly used today, including the natriuretic peptides, BNP and NT-proBNP.
Critical Diagnostics was founded in 2004. The Company
licensed intellectual property discovered in 2002 at Brigham and Women's
Hospital relating to ST2, for which it now holds the exclusive worldwide
rights. The company has since expanded its intellectual property portfolio and
holds several issued patents in the US and abroad as well as numerous patents
Critical Diagnostics is a privately-held company.
our mission statement
To build shareholder value by delivering healthcare
solutions that save and improve patients’ lives, and to do that in cost
effective ways. We will realize this mission by focusing on quality: setting
the highest standards in the products we produce, the service we provide, and
the care we put into everything we do.